| ECM | Extracellular matrix |
| HFpEF | Heart failure with preserved ejection fraction |
| HG | High glucose |
| α-SMA | Alpha smooth muscle actin |
| ang II | Angiotensin II |
| AT1 | Angiotensin 1 |
| ACE | Angiotensin-converting enzyme |
| TGF-β | Transforming growth factor beta |
| ERK | Extracellular signal-regulated kinases |
| TSP1 | Thrombospondin 1 |
| Akt | Protein kinase B |
| AMPK | Activation of adenosine monophosphate-activated protein kinase |
| PI3 | Phosphoinositide 3-kinase |
| EGF | Epidermal growth factor |
| AGEs | Advanced glycation end products |
| NF-κB | Nuclear factor kappa B |
| RAGE | Receptor for advanced glycation end products |
| IL | Interleukin |
| O-GlcNAc | O-GlcNAcylation |
| HMGB1 | High-mobility group box 1 |
| TLR4 | Toll-like receptor 4 |
| MMP | Matrix metalloproteinase |
| TIMP | Tissue inhibitor of metalloproteinase |
| miRNA | MicroRNA |
| JNK | c-Jun N-terminal kinase |
| MEF2 | Myocyte enhancer factor 2 |
| NO | Nitric oxide |
| iNOS | Inducible nitric oxide synthase |
| H2O2 | Hydrogen peroxide |
| NOD1 | Nucleotide oligomerization-binding domain 1 |
| MeCP2 | Methyl CpG-binding protein 2 |
| RASSF1A | Ras association domain family 1 isoform A |
| PAR-4 | Protease activated receptor 4 |